Two private financings reinforced investor appetite for engineered‑T and T‑cell engager platforms. Crossbow Therapeutics closed a $77 million Series B to advance T‑cell‑receptor‑mimetic immunotherapies including lead CBX‑250 into a Phase 1 program, pairing university discovery with translational funding. Excalipoint Therapeutics launched with an oversubscribed $68.7 million seed round to develop multi‑specific T‑cell engager platforms in China and support a diversified pipeline. Both financings signal renewed venture capital interest in next‑generation immune engagers that aim to broaden solid‑tumor reach while limiting toxicities.